NovaBay [NBY] vs Orchestra BioMed [OBIO] Detailed Stock Comparison

NovaBay Pharmaceuticals, Inc.

NYSE
Loading...

Orchestra BioMed Holdings, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: NovaBay Pharmaceuticals, Inc. wins in 7 metrics, Orchestra BioMed Holdings, Inc. wins in 8 metrics, with 0 ties. Orchestra BioMed Holdings, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric NovaBay Pharmaceuticals, Inc. Orchestra BioMed Holdings, Inc. Better
P/E Ratio (TTM) 0.04 N/A N/A
Price-to-Book Ratio N/A 4.48 N/A
Debt-to-Equity Ratio -0.03 25.17 Orchestra BioMed Holdings, Inc.
PEG Ratio -2.38 -2.47 NovaBay Pharmaceuticals, Inc.
EV/EBITDA -5.95 -3.22 Orchestra BioMed Holdings, Inc.
Profit Margin (TTM) 0.00% -157.40% NovaBay Pharmaceuticals, Inc.
Operating Margin (TTM) 350.10% 21.85% NovaBay Pharmaceuticals, Inc.
EBITDA Margin (TTM) 350.10% 21.85% NovaBay Pharmaceuticals, Inc.
Return on Equity 95.53% -109.41% NovaBay Pharmaceuticals, Inc.
Return on Assets (TTM) -76.11% -33.90% Orchestra BioMed Holdings, Inc.
Free Cash Flow (TTM) $-8.43M $-49.45M NovaBay Pharmaceuticals, Inc.
1-Year Return -53.82% 37.19% Orchestra BioMed Holdings, Inc.
Price-to-Sales Ratio (TTM) N/A 7.36 N/A
Enterprise Value $45.09M $165.62M Orchestra BioMed Holdings, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 99.84% N/A
Revenue per Share (TTM) $0 $1 Orchestra BioMed Holdings, Inc.
Earnings per Share (Diluted) $-28.50 $-1.11 Orchestra BioMed Holdings, Inc.
Beta (Stock Volatility) 0.16 0.60 NovaBay Pharmaceuticals, Inc.
Short % of Float 9.79% 2.46% Orchestra BioMed Holdings, Inc.

NovaBay Pharmaceuticals, Inc. vs Orchestra BioMed Holdings, Inc. Stock Performance Analysis

Loading Price Chart...

NBY
OBIO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NovaBay Pharmaceuticals, Inc.0.87%-17.14%-11.45%-21.62%-78.11%-96.05%
Orchestra BioMed Holdings, Inc.-1.28%-2.28%-3.98%-11.47%-20.58%-10.44%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NovaBay Pharmaceuticals, Inc.-53.82%-98.79%-99.97%-99.99%-100.00%-100.00%
Orchestra BioMed Holdings, Inc.37.19%-75.14%-61.44%-51.73%-51.73%-51.73%

Performance & Financial Health Analysis: NovaBay Pharmaceuticals, Inc. vs Orchestra BioMed Holdings, Inc.

MetricNBYOBIO
Market Information
Market Cap i$34.35M$242.86M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i186,830133,035
90 Day Avg. Volume i486,346183,128
Last Close$1.16$3.86
52 Week Range$1.08 - $99.75$2.20 - $5.42
% from 52W High-98.84%-28.83%
All-Time High$130,156.25 (Oct 22, 2007)$23.39 (Apr 03, 2023)
% from All-Time High-100.00%-83.50%
Growth Metrics
Quarterly Revenue Growth-2.00%121.20%
Quarterly Earnings Growth-1.23%121.20%
Financial Health
Profit Margin (TTM) i0.00%-1.57%
Operating Margin (TTM) i3.50%0.22%
Return on Equity (TTM) i0.96%-1.09%
Debt to Equity (MRQ) i-0.0325.17
Cash & Liquidity
Book Value per Share (MRQ)$-0.92$0.94
Cash per Share (MRQ)$0.30$1.82
Operating Cash Flow (TTM) i$2.70M$-48,963,000
Levered Free Cash Flow (TTM) i$-4,935,750$-20,247,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i$0.00N/A

Valuation & Enterprise Metrics Analysis: NovaBay Pharmaceuticals, Inc. vs Orchestra BioMed Holdings, Inc.

MetricNBY (Apr 24, 2026)OBIO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i0.04N/A
Forward P/E i-2.38-2.47
PEG Ratio i-2.38-2.47
Price to Sales (TTM) iN/A7.36
Price to Book (MRQ) iN/A4.48
Market Capitalization
Market Capitalization i$34.35M$242.86M
Enterprise Value i$45.09M$165.62M
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i-5.95-3.22
Risk & Other Metrics
Beta i0.160.60
Book Value per Share (MRQ) i$-0.92$0.94

Financial Statements Comparison: NovaBay Pharmaceuticals, Inc. vs Orchestra BioMed Holdings, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBY (2025)OBIO (2025)
Revenue/Sales i033.48M
Cost of Goods Sold iN/A190,000
COGS % of Revenue i-0.6%
Gross Profit iN/A33.29M
Gross Margin i-99.4%
Research & Development iN/A58.19M
Operating Income (EBIT) i-7.59M-51.81M
Operating Margin i--154.7%
EBITDA i-7.47M-51.48M
EBITDA Margin i--153.8%
Pre-Tax Income i-33.22M-52.70M
Pre-Tax Income % of Revenue i--157.4%
Income Tax iN/AN/A
Income Tax % of Revenue i-0.0%
Net Income (Profit) i-22.14M-52.70M
Profit Margin i--157.4%

Balance Sheet & Liquidity Metrics

MetricNBY (2025)OBIO (2025)
Cash & Equivalents i7.96M34.69M
Total Current Assets i8.68M107.91M
Total Current Assets % of Revenue i-322.3%
Total Current Liabilities i1.14M16.74M
Total Current Liabilities % of Revenue i-50.0%
Long-Term Debt i287,00015.20M
Long-Term Debt % of Revenue i-45.4%
Total Shareholders Equity i-23.18M53.57M
Retained Earnings i-210.42M-362.58M
Retained Earnings % of Revenue i--1,082.9%
Property, Plant & Equipment i04.24M

Cash Flow Statement Comparison

MetricNBY (2025)OBIO (2025)
Operating Cash Flow i-33.33M-54.46M
Operating Cash Flow % of Revenue i--162.6%
Capital Expenditures iN/A-489,000
Free Cash Flow i-8.43M-49.45M
FCF Margin i--147.7%
Debt Repayment i-2.50MN/A
Common Stock Repurchase i-175,000N/A

Short Interest & Institutional Ownership Analysis

MetricNBYOBIO
Shares Short i333,120957,939
Short Ratio i0.693.91
Short % of Float i9.79%2.46%
Shares Outstanding i25.22M57.03M
Float Shares i2.62M32.49M
% Held by Insiders i90.14%27.92%
% Held by Institutions i5.34%38.23%
% Held by Public i4.52%33.85%

Dividend Analysis & Yield Comparison: NovaBay Pharmaceuticals, Inc. vs Orchestra BioMed Holdings, Inc.

MetricNBYOBIO
Last 12-Month Dividend i$0.00N/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i$0.00N/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i$0.00N/A
Ex-Dividend DateN/AN/A